University of Groningen
Improving antimicrobial therapy for Buruli ulcer
Omansen, Till Frederik
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Omansen, T. F. (2019). Improving antimicrobial therapy for Buruli ulcer: Pre-clinical studies towards highly
efficient, short-course therapy. University of Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Propositions PhD Thesis Till Omansen
1. Buruli ulcer control should focus on early case detection and short, efficient
antimicrobial treatment.
2. A map is only as good as the data going into it. Digital tools can help to
improve to describe the epidemiology of neglected tropical diseases.
3. Bioluminescence and imaging in the mouse footpad model will help decipher
complex lesion pathology and pharmacokinetics in Buruli ulcer.
4. Avermectins are “wonder drugs” for onchocerciasis and other helminths,
malaria and cancer, even if they have no major impact on Buruli ulcer.
5. High-dose rifampin should be the backbone for future short-course Buruli
ulcer regimens considering that high dosing is safe in humans and highly
effective in the mouse model of M. ulcerans infection.
6. Clarithromycin as a companion to rifampicin drug treatment for Buruli ulcer
should be replaced by either azithromycin, oxazolidinones, or newer anti-mycobacterial agents in future studies.
7. Considering that no one should be left behind, drug research for Neglected
Tropical Diseases should not only focus on repurposing drugs but also on
developing and employing new drugs.
8. Co-endemicity mapping and joint meetings regarding skin Neglected Tropical
Diseases should be the first step to increase collaboration and integration of
research, disease control and case management.
9. Skin Neglected Tropical Diseases like Buruli ulcer, leprosy, mycetoma,
chromoblastomycosis, cutaneous leishmaniasis and Noma receive less
attention as they may be crippling but do not kill.
10. Buruli ulcer research sets a successful and beautiful example of global
collaboration and friendship to improve the life of patients.
